APO Research
Talk to an analyst

APO RESEARCH · REPORT

Respiratory Syncytial Virus Vaccine for the Elderly

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Respiratory Syncytial Virus Vaccine for the Elderly Market Analysis and Forecast 2026-2032

27 December 2025197 pages

Choose your research edition.

Industry ResearchRespiratory Syncytial Virus Vaccine for the Elderly Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Respiratory Syncytial Virus Vaccine for the Elderly Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Respiratory Syncytial Virus Vaccine for the Elderly Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Respiratory Syncytial Virus Vaccine for the Elderly Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Respiratory Syncytial Virus Vaccine for the Elderly Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Respiratory Syncytial Virus Vaccine for the Elderly market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Respiratory Syncytial Virus Vaccine for the Elderly is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Respiratory Syncytial Virus Vaccine for the Elderly is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Respiratory Syncytial Virus Vaccine for the Elderly is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Respiratory Syncytial Virus Vaccine for the Elderly is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Respiratory Syncytial Virus Vaccine for the Elderly include GSK, Icosavax, Moderna, Pfizer, RNAimmune, Sanofi, Advaccine, Daiichi Sankyo and Immorna, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Respiratory Syncytial Virus Vaccine for the Elderly, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Respiratory Syncytial Virus Vaccine for the Elderly, also provides the sales of main regions and countries. Of the upcoming market potential for Respiratory Syncytial Virus Vaccine for the Elderly, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Respiratory Syncytial Virus Vaccine for the Elderly sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Respiratory Syncytial Virus Vaccine for the Elderly market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Respiratory Syncytial Virus Vaccine for the Elderly sales, projected growth trends, production technology, application and end-user industry.

Respiratory Syncytial Virus Vaccine for the Elderly Segment by Company

GSK

Icosavax

Moderna

Pfizer

RNAimmune

Sanofi

Advaccine

Daiichi Sankyo

Immorna

Blue Lake Biotechnology

Clover Biopharma

Innorna

Starna Therapeutics

Respiratory Syncytial Virus Vaccine for the Elderly Segment by Type

Recombinant Protein Vaccine

Nucleic Acid Vaccines

Others

Respiratory Syncytial Virus Vaccine for the Elderly Segment by Application

Hospital

Centers for Disease Control and Prevention

Others

Respiratory Syncytial Virus Vaccine for the Elderly Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Respiratory Syncytial Virus Vaccine for the Elderly market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Respiratory Syncytial Virus Vaccine for the Elderly and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Respiratory Syncytial Virus Vaccine for the Elderly.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Respiratory Syncytial Virus Vaccine for the Elderly in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Respiratory Syncytial Virus Vaccine for the Elderly manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Respiratory Syncytial Virus Vaccine for the Elderly sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Recombinant Protein Vaccine Major Manufacturers Table 3. Nucleic Acid Vaccines Major Manufacturers Table 4. Others Major Manufacturers Table 5. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospital Major Manufacturers Table 7. Centers for Disease Control and Prevention Major Manufacturers Table 8. Others Major Manufacturers Table 9. Respiratory Syncytial Virus Vaccine for the Elderly Industry Trends Table 10. Respiratory Syncytial Virus Vaccine for the Elderly Industry Drivers Table 11. Respiratory Syncytial Virus Vaccine for the Elderly Industry Opportunities and Challenges Table 12. Respiratory Syncytial Virus Vaccine for the Elderly Industry Restraints Table 13. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 14. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region (2021-2026) & (US$ Million) Table 15. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region (2027-2032) & (US$ Million) Table 16. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Region (2021-2026) Table 17. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Region (2027-2032) Table 18. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (Units) Table 19. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2021-2026) & (Units) Table 20. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2027-2032) & (Units) Table 21. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Region (2021-2026) Table 22. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Region (2027-2032) Table 23. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Manufacturers (2021-2026) Table 25. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Manufacturers (2021-2026) Table 27. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 28. Global Respiratory Syncytial Virus Vaccine for the Elderly Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 29. Global Respiratory Syncytial Virus Vaccine for the Elderly Key Manufacturers Manufacturing Sites & Headquarters Table 30. Global Respiratory Syncytial Virus Vaccine for the Elderly Manufacturers, Product Type & Application Table 31. Global Respiratory Syncytial Virus Vaccine for the Elderly Manufacturers' Establishment Date Table 32. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 33. Global Respiratory Syncytial Virus Vaccine for the Elderly by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 34. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2021-2026) & (US$ Million) Table 36. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2027-2032) & (US$ Million) Table 37. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Type (2021-2026) Table 38. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Type (2027-2032) Table 39. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type 2021 VS 2025 VS 2032 (Units) Table 40. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (Units) Table 41. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2027-2032) & (Units) Table 42. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2021-2026) Table 43. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2027-2032) Table 44. Global Respiratory Syncytial Virus Vaccine for the Elderly Price by Type (2021-2026) & (US$/Unit) Table 45. Global Respiratory Syncytial Virus Vaccine for the Elderly Price by Type (2027-2032) & (US$/Unit) Table 46. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2021-2026) & (US$ Million) Table 48. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2027-2032) & (US$ Million) Table 49. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Application (2021-2026) Table 50. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Application (2027-2032) Table 51. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application 2021 VS 2025 VS 2032 (Units) Table 52. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (Units) Table 53. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2027-2032) & (Units) Table 54. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application (2021-2026) Table 55. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application (2027-2032) Table 56. Global Respiratory Syncytial Virus Vaccine for the Elderly Price by Application (2021-2026) & (US$/Unit) Table 57. Global Respiratory Syncytial Virus Vaccine for the Elderly Price by Application (2027-2032) & (US$/Unit) Table 58. GSK Company Information Table 59. GSK Business Overview Table 60. GSK Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. GSK Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 62. GSK Recent Development Table 63. Icosavax Company Information Table 64. Icosavax Business Overview Table 65. Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 67. Icosavax Recent Development Table 68. Moderna Company Information Table 69. Moderna Business Overview Table 70. Moderna Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Moderna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 72. Moderna Recent Development Table 73. Pfizer Company Information Table 74. Pfizer Business Overview Table 75. Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 77. Pfizer Recent Development Table 78. RNAimmune Company Information Table 79. RNAimmune Business Overview Table 80. RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 82. RNAimmune Recent Development Table 83. Sanofi Company Information Table 84. Sanofi Business Overview Table 85. Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 87. Sanofi Recent Development Table 88. Advaccine Company Information Table 89. Advaccine Business Overview Table 90. Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 92. Advaccine Recent Development Table 93. Daiichi Sankyo Company Information Table 94. Daiichi Sankyo Business Overview Table 95. Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 97. Daiichi Sankyo Recent Development Table 98. Immorna Company Information Table 99. Immorna Business Overview Table 100. Immorna Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Immorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 102. Immorna Recent Development Table 103. Blue Lake Biotechnology Company Information Table 104. Blue Lake Biotechnology Business Overview Table 105. Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 107. Blue Lake Biotechnology Recent Development Table 108. Clover Biopharma Company Information Table 109. Clover Biopharma Business Overview Table 110. Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 112. Clover Biopharma Recent Development Table 113. Innorna Company Information Table 114. Innorna Business Overview Table 115. Innorna Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Innorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 117. Innorna Recent Development Table 118. Starna Therapeutics Company Information Table 119. Starna Therapeutics Business Overview Table 120. Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio Table 122. Starna Therapeutics Recent Development Table 123. North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2021-2026) & (US$ Million) Table 124. North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2027-2032) & (US$ Million) Table 125. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (Units) Table 126. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2027-2032) & (Units) Table 127. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Price by Type (2021-2026) & (US$/Unit) Table 128. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Price by Type (2027-2032) & (US$/Unit) Table 129. North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2021-2026) & (US$ Million) Table 130. North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2027-2032) & (US$ Million) Table 131. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (Units) Table 132. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2027-2032) & (Units) Table 133. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Price by Application (2021-2026) & (US$/Unit) Table 134. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Price by Application (2027-2032) & (US$/Unit) Table 135. North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 136. North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 137. North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 138. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021 VS 2025 VS 2032) & (Units) Table 139. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026) & (Units) Table 140. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2027-2032) & (Units) Table 141. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Price by Country (2021-2026) & (US$/Unit) Table 142. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Price by Country (2027-2032) & (US$/Unit) Table 143. United States Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Table 144. Canada Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Table 145. Mexico Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Table 146. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2021-2026) & (US$ Million) Table 147. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2027-2032) & (US$ Million) Table 148. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (Units) Table 149. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2027-2032) & (Units) Table 150. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Price by Type (2021-2026) & (US$/Unit) Table 151. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Price by Type (2027-2032) & (US$/Unit) Table 152. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2021-2026) & (US$ Million) Table 153. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2027-2032) & (US$ Million) Table 154. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (Units) Table 155. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2027-2032) & (Units) Table 156. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Price by Application (2021-2026) & (US$/Unit) Table 157. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Price by Application (2027-2032) & (US$/Unit) Table 158. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 159. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 160. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 161. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021 VS 2025 VS 2032) & (Units) Table 162. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026) & (Units) Table 163. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2027-2032) & (Units) Table 164. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Price by Country (2021-2026) & (US$/Unit) Table 165. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Price by Country (2027-2032) & (US$/Unit) Table 166. Germany Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Table 167. France Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Table 168. U.K. Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Table 169. Italy Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Table 170. Russia Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Table 171. Spain Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Table 172. Netherlands Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Table 173. Switzerland Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Table 174. Sweden Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Table 175. Poland Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Table 176. China Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2021-2026) & (US$ Million) Table 177. China Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2027-2032) & (US$ Million) Table 178. China Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (Units) Table 179. China Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2027-2032) & (Units) Table 180. China Respiratory Syncytial Virus Vaccine for the Elderly Sales Price by Type (2021-2026) & (US$/Unit) Table 181. China Respiratory Syncytial Virus Vaccine for the Elderly Sales Price by Type (2027-2032) & (US$/Unit) Table 182. China Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2021-2026) & (US$ Million) Table 183. China Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2027-2032) & (US$ Million) Table 184. China Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (Units) Table 185. China Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2027-2032) & (Units) Table 186. China Respiratory Syncytial Virus Vaccine for the Elderly Sales Price by Application (2021-2026) & (US$/Unit) Table 187. China Respiratory Syncytial Virus Vaccine for the Elderly Sales Price by Application (2027-2032) & (US$/Unit) Table 188. Asia Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2021-2026) & (US$ Million) Table 189. Asia Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2027-2032) & (US$ Million) Table 190. Asia Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (Units) Table 191. Asia Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2027-2032) & (Units) Table 192. Asia Respiratory Syncytial Virus Vaccine for the Elderly Sales Price by Type (2021-2026) & (US$/Unit) Table 193. Asia Respiratory Syncytial Virus Vaccine for the Elderly Sales Price by Type (2027-2032) & (US$/Unit) Table 194. Asia Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2021-2026) & (US$ Million) Table 195. Asia Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2027-2032) & (US$ Million) Table 196. Asia Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (Units) Table 197. Asia Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2027-2032) & (Units) Table 198. Asia Respiratory Syncytial Virus Vaccine for the Elderly Sales Price by Application (2021-2026) & (US$/Unit) Table 199. Asia Respiratory Syncytial Virus Vaccine for the Elderly Sales Price by Application (2027-2032) & (US$/Unit) Table 200. Asia Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 201. Asia Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 202. Asia Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 203. Asia Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021 VS 2025 VS 2032) & (Units) Table 204. Asia Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026) & (Units) Table 205. Asia Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2027-2032) & (Units) Table 206. Asia Respiratory Syncytial Virus Vaccine for the Elderly Sales Price by Country (2021-2026) & (US$/Unit) Table 207. Asia Respiratory Syncytial Virus Vaccine for the Elderly Sales Price by Country (2027-2032) & (US$/Unit) Table 208. Japan Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Table 209. South Korea Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Table 210. India Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Table 211. Australia Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Table 212. Taiwan Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Table 213. Southeast Asia Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Table 214. SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2021-2026) & (US$ Million) Table 215. SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2027-2032) & (US$ Million) Table 216. SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (Units) Table 217. SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2027-2032) & (Units) Table 218. SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Sales Price by Type (2021-2026) & (US$/Unit) Table 219. SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Sales Price by Type (2027-2032) & (US$/Unit) Table 220. SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2021-2026) & (US$ Million) Table 221. SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2027-2032) & (US$ Million) Table 222. SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (Units) Table 223. SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2027-2032) & (Units) Table 224. SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Sales Price by Application (2021-2026) & (US$/Unit) Table 225. SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Sales Price by Application (2027-2032) & (US$/Unit) Table 226. SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 227. SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 228. SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 229. SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021 VS 2025 VS 2032) & (Units) Table 230. SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026) & (Units) Table 231. SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2027-2032) & (Units) Table 232. SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Sales Price by Country (2021-2026) & (US$/Unit) Table 233. SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Sales Price by Country (2027-2032) & (US$/Unit) Table 234. Brazil Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Table 235. Argentina Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Table 236. Chile Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Table 237. Colombia Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Table 238. Peru Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Table 239. Saudi Arabia Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Table 240. Israel Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Table 241. UAE Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Table 242. Turkey Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Table 243. Iran Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Table 244. Egypt Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Table 245. Key Raw Materials Table 246. Raw Materials Key Suppliers Table 247. Respiratory Syncytial Virus Vaccine for the Elderly Distributors List Table 248. Respiratory Syncytial Virus Vaccine for the Elderly Customers List Table 249. Research Programs/Design for This Report Table 250. Authors List of This Report Table 251. Secondary Sources Table 252. Primary Sources List of Figures Figure 1. Respiratory Syncytial Virus Vaccine for the Elderly Image Figure 2. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size Share 2021 VS 2025 VS 2032 Figure 4. Recombinant Protein Vaccine Image Figure 5. Nucleic Acid Vaccines Image Figure 6. Others Image Figure 7. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospital Image Figure 10. Centers for Disease Control and Prevention Image Figure 11. Others Image Figure 12. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue (2021-2032) & (US$ Million) Figure 14. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 15. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Region: 2025 Versus 2032 Figure 16. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Region (2021-2032) Figure 17. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales (2021-2032) & (Units) Figure 18. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region: 2021 VS 2025 VS 2032 (Units) Figure 19. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Region (2021-2032) Figure 20. US & Canada & Mexico Respiratory Syncytial Virus Vaccine for the Elderly Sales YoY (2021-2032) & (Units) Figure 21. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales YoY (2021-2032) & (Units) Figure 22. China Respiratory Syncytial Virus Vaccine for the Elderly Sales YoY (2021-2032) & (Units) Figure 23. Asia (Excluding China) Respiratory Syncytial Virus Vaccine for the Elderly Sales YoY (2021-2032) & (Units) Figure 24. South America, Middle East and Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales YoY (2021-2032) & (Units) Figure 25. Global Respiratory Syncytial Virus Vaccine for the Elderly Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 26. Global Respiratory Syncytial Virus Vaccine for the Elderly Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 27. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 28. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 30. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Type (2021-2032) Figure 31. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021 VS 2025 VS 2032) & (Units) Figure 32. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2021-2032) Figure 34. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 35. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 36. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Application (2021-2032) Figure 37. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021 VS 2025 VS 2032) & (Units) Figure 38. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application (2021-2032) Figure 40. North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue Share by Type (2021-2032) Figure 41. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Share by Type (2021-2032) Figure 42. North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue Share by Application (2021-2032) Figure 43. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Share by Application (2021-2032) Figure 44. North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue Share by Country (2021-2032) Figure 45. North America Respiratory Syncytial Virus Vaccine for the Elderly Sales Share by Country (2021-2032) Figure 46. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue Share by Type (2021-2032) Figure 47. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Share by Type (2021-2032) Figure 48. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue Share by Application (2021-2032) Figure 49. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Share by Application (2021-2032) Figure 50. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue Share by Country (2021-2032) Figure 51. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Share by Country (2021-2032) Figure 52. China Respiratory Syncytial Virus Vaccine for the Elderly Revenue Share by Type (2021-2032) Figure 53. China Respiratory Syncytial Virus Vaccine for the Elderly Sales Share by Type (2021-2032) Figure 54. China Respiratory Syncytial Virus Vaccine for the Elderly Revenue Share by Application (2021-2032) Figure 55. China Respiratory Syncytial Virus Vaccine for the Elderly Sales Share by Application (2021-2032) Figure 56. Asia Respiratory Syncytial Virus Vaccine for the Elderly Revenue Share by Type (2021-2032) Figur

Scope & coverage.

Types
  • Recombinant Protein Vaccine
  • Nucleic Acid Vaccines
  • Others
Applications
  • Hospital
  • Centers for Disease Control and Prevention
  • Others
Companies covered
  • GSK
  • Icosavax
  • Moderna
  • Pfizer
  • RNAimmune
  • Sanofi
  • Advaccine
  • Daiichi Sankyo
  • Immorna
  • Blue Lake Biotechnology
  • Clover Biopharma
  • Innorna
  • Starna Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Respiratory Syncytial Virus Vaccine for the Elderly Market by Type
  3. 1.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Recombinant Protein Vaccine
  5. 1.2.3 Nucleic Acid Vaccines
  6. 1.2.4 Others
  7. 1.3 Respiratory Syncytial Virus Vaccine for the Elderly Market by Application
  8. 1.3.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospital
  10. 1.3.3 Centers for Disease Control and Prevention
  11. 1.3.4 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Respiratory Syncytial Virus Vaccine for the Elderly Market Dynamics
  1. 2.1 Respiratory Syncytial Virus Vaccine for the Elderly Industry Trends
  2. 2.2 Respiratory Syncytial Virus Vaccine for the Elderly Industry Drivers
  3. 2.3 Respiratory Syncytial Virus Vaccine for the Elderly Industry Opportunities and Challenges
  4. 2.4 Respiratory Syncytial Virus Vaccine for the Elderly Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region
  3. 3.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region (2021-2026)
  5. 3.2.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region (2027-2032)
  6. 3.2.4 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region
  9. 3.4.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2021-2026)
  11. 3.4.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2027-2032)
  12. 3.4.4 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Manufacturers
  2. 4.1.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Manufacturers
  6. 4.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Respiratory Syncytial Virus Vaccine for the Elderly Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Respiratory Syncytial Virus Vaccine for the Elderly Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Respiratory Syncytial Virus Vaccine for the Elderly Manufacturers, Product Type & Application
  13. 4.7 Global Respiratory Syncytial Virus Vaccine for the Elderly Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Market CR5 and HHI
  16. 4.8.2 2025 Respiratory Syncytial Virus Vaccine for the Elderly Tier 1, Tier 2, and Tier 3
5 Respiratory Syncytial Virus Vaccine for the Elderly Market by Type
  1. 5.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type
  2. 5.1.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type
  6. 5.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2032) & (Units)
  8. 5.2.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2021-2032)
  9. 5.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Price by Type
6 Respiratory Syncytial Virus Vaccine for the Elderly Market by Application
  1. 6.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application
  2. 6.1.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application
  6. 6.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2032) & (Units)
  8. 6.2.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application (2021-2032)
  9. 6.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Price by Application
7 Company Profiles
  1. 7.1 GSK
  2. 7.1.1 GSK Company Information
  3. 7.1.2 GSK Business Overview
  4. 7.1.3 GSK Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 GSK Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  6. 7.1.5 GSK Recent Developments
  7. 7.2 Icosavax
  8. 7.2.1 Icosavax Company Information
  9. 7.2.2 Icosavax Business Overview
  10. 7.2.3 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  12. 7.2.5 Icosavax Recent Developments
  13. 7.3 Moderna
  14. 7.3.1 Moderna Company Information
  15. 7.3.2 Moderna Business Overview
  16. 7.3.3 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  18. 7.3.5 Moderna Recent Developments
  19. 7.4 Pfizer
  20. 7.4.1 Pfizer Company Information
  21. 7.4.2 Pfizer Business Overview
  22. 7.4.3 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  24. 7.4.5 Pfizer Recent Developments
  25. 7.5 RNAimmune
  26. 7.5.1 RNAimmune Company Information
  27. 7.5.2 RNAimmune Business Overview
  28. 7.5.3 RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  30. 7.5.5 RNAimmune Recent Developments
  31. 7.6 Sanofi
  32. 7.6.1 Sanofi Company Information
  33. 7.6.2 Sanofi Business Overview
  34. 7.6.3 Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  36. 7.6.5 Sanofi Recent Developments
  37. 7.7 Advaccine
  38. 7.7.1 Advaccine Company Information
  39. 7.7.2 Advaccine Business Overview
  40. 7.7.3 Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  42. 7.7.5 Advaccine Recent Developments
  43. 7.8 Daiichi Sankyo
  44. 7.8.1 Daiichi Sankyo Company Information
  45. 7.8.2 Daiichi Sankyo Business Overview
  46. 7.8.3 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  48. 7.8.5 Daiichi Sankyo Recent Developments
  49. 7.9 Immorna
  50. 7.9.1 Immorna Company Information
  51. 7.9.2 Immorna Business Overview
  52. 7.9.3 Immorna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Immorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  54. 7.9.5 Immorna Recent Developments
  55. 7.10 Blue Lake Biotechnology
  56. 7.10.1 Blue Lake Biotechnology Company Information
  57. 7.10.2 Blue Lake Biotechnology Business Overview
  58. 7.10.3 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  60. 7.10.5 Blue Lake Biotechnology Recent Developments
  61. 7.11 Clover Biopharma
  62. 7.11.1 Clover Biopharma Company Information
  63. 7.11.2 Clover Biopharma Business Overview
  64. 7.11.3 Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  66. 7.11.5 Clover Biopharma Recent Developments
  67. 7.12 Innorna
  68. 7.12.1 Innorna Company Information
  69. 7.12.2 Innorna Business Overview
  70. 7.12.3 Innorna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Innorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  72. 7.12.5 Innorna Recent Developments
  73. 7.13 Starna Therapeutics
  74. 7.13.1 Starna Therapeutics Company Information
  75. 7.13.2 Starna Therapeutics Business Overview
  76. 7.13.3 Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolio
  78. 7.13.5 Starna Therapeutics Recent Developments
8 North America
  1. 8.1 North America Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Type
  2. 8.1.1 North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2021-2032)
  3. 8.1.2 North America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2032)
  4. 8.1.3 North America Respiratory Syncytial Virus Vaccine for the Elderly Price by Type (2021-2032)
  5. 8.2 North America Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Application
  6. 8.2.1 North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2021-2032)
  7. 8.2.2 North America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2032)
  8. 8.2.3 North America Respiratory Syncytial Virus Vaccine for the Elderly Price by Application (2021-2032)
  9. 8.3 North America Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country
  10. 8.3.1 North America Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Respiratory Syncytial Virus Vaccine for the Elderly Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Type
  2. 9.1.1 Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2021-2032)
  3. 9.1.2 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2032)
  4. 9.1.3 Europe Respiratory Syncytial Virus Vaccine for the Elderly Price by Type (2021-2032)
  5. 9.2 Europe Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Application
  6. 9.2.1 Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2021-2032)
  7. 9.2.2 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2032)
  8. 9.2.3 Europe Respiratory Syncytial Virus Vaccine for the Elderly Price by Application (2021-2032)
  9. 9.3 Europe Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country
  10. 9.3.1 Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Respiratory Syncytial Virus Vaccine for the Elderly Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Type
  2. 10.1.1 China Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2021-2032)
  3. 10.1.2 China Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2032)
  4. 10.1.3 China Respiratory Syncytial Virus Vaccine for the Elderly Price by Type (2021-2032)
  5. 10.2 China Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Application
  6. 10.2.1 China Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2021-2032)
  7. 10.2.2 China Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2032)
  8. 10.2.3 China Respiratory Syncytial Virus Vaccine for the Elderly Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Type
  2. 11.1.1 Asia Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2021-2032)
  3. 11.1.2 Asia Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2032)
  4. 11.1.3 Asia Respiratory Syncytial Virus Vaccine for the Elderly Price by Type (2021-2032)
  5. 11.2 Asia Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Application
  6. 11.2.1 Asia Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2021-2032)
  7. 11.2.2 Asia Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2032)
  8. 11.2.3 Asia Respiratory Syncytial Virus Vaccine for the Elderly Price by Application (2021-2032)
  9. 11.3 Asia Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country
  10. 11.3.1 Asia Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Respiratory Syncytial Virus Vaccine for the Elderly Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Type
  2. 12.1.1 SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Price by Type (2021-2032)
  5. 12.2 SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Application
  6. 12.2.1 SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Price by Application (2021-2032)
  9. 12.3 SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country
  10. 12.3.1 SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Respiratory Syncytial Virus Vaccine for the Elderly Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Respiratory Syncytial Virus Vaccine for the Elderly Value Chain Analysis
  2. 13.1.1 Respiratory Syncytial Virus Vaccine for the Elderly Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Respiratory Syncytial Virus Vaccine for the Elderly Production Mode & Process
  6. 13.2 Respiratory Syncytial Virus Vaccine for the Elderly Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Respiratory Syncytial Virus Vaccine for the Elderly Distributors
  9. 13.2.3 Respiratory Syncytial Virus Vaccine for the Elderly Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst